INCY Incyte
FY2025 10-K
Incyte (INCY) filed its fiscal year 2025 10-K annual report with the SEC on Feb 10, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Biopharmaceutical company focused on development, commercialization, and licensing of innovative drugs
- • New products emphasized: NIKTIMVO commercial launch in Q1 2025; ZYNYZ approved for squamous cell anal carcinoma in Q2 2025
Management Discussion & Analysis
- • Revenue $3.5B, up 8% YoY driven by JAKAFI and new product growth
- • Operating margin 22.4% vs 19.7% reflecting improved cost efficiencies
Risk Factors
- • Regulatory risk: ongoing contract dispute settlement expense of $242M recognized in fiscal 2025
- • Macroeconomic exposure: 93% of total revenues ($4.8B of $5.1B) from U.S. market concentration
Financial SummaryXBRL
Revenue
$5.1B
Net Income
$1.3B
Operating Margin
29.5%
Net Margin
25.0%
ROE
24.9%
Total Assets
$7.0B
EPS (Diluted)
$6.41
Operating Cash Flow
$1.4B
Source: XBRL data from Incyte FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Incyte
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.